Clinical Scorecard: Retinal Clinical Trials in AMD, DME, RVO, and Uveitis
At a Glance
| Category | Detail |
|---|---|
| Condition | The source lists clinical trials in AMD, DME, RVO, and uveitis; the supplied trial descriptions focus on AMD, with two terminated studies noted in the introduction. |
| Key Mechanisms | Described study approaches include oral and intravitreal agents, subretinal injection, dietary intervention, and imaging assessments; the source does not specify mechanisms for all interventions. |
| Target Population | Described populations include adults with geographic atrophy secondary to AMD, participants with intermediate AMD, healthy participants and participants with AMD, and patients undergoing intravitreal injections. |
| Care Setting | The source describes multicenter and single-center studies, as well as a pilot comparative imaging study; it does not otherwise specify care settings. |
Key Highlights
- The listing includes trials in AMD, DME, RVO, and uveitis, while the supplied trial descriptions focus on AMD.
- Several described studies investigate geographic atrophy secondary to AMD, including phase 2 and phase 3 trials.
- Described approaches include oral and intravitreal agents, a single subretinal injection, dietary intervention, and imaging assessments.
- The introduction identifies RO7669330 for geographic atrophy and REGN7041 for active noninfectious uveitis as terminated.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Eligibility is study-specific. Described examples include adults with geographic atrophy secondary to AMD, participants with intermediate AMD, healthy participants and participants with AMD, and patients undergoing intravitreal injections.
The source describes investigational protocols rather than prescribing guidance. Listed approaches include oral STL303, SGLT2 inhibitors, intravitreal agents, a single subretinal injection of CTx001, dietary intervention, and comparisons of ocular surface anesthesia.
Clinical Best Practices
- The source is a trial listing and does not state clinical diagnosis or treatment recommendations.
Related Resources & Content
- ClinicalTrials.gov: RO7669330 in geographic atrophy (NCT06961370)
- ClinicalTrials.gov: REGN7041 for active noninfectious uveitis (NCT07218770)
- ClinicalTrials.gov: OCU410 for geographic atrophy (NCT07770828)
- ClinicalTrials.gov: Adaptive optics and microperimetry substudy (NCT07747662)
- ClinicalTrials.gov: GLOVE dietary intervention study (NCT07605468)
- ClinicalTrials.gov: STL303 in geographic atrophy (NCT07606365)
- ClinicalTrials.gov: FWY003 in geographic atrophy (NCT07441642)
- ClinicalTrials.gov: QUELL anesthesia study (NCT07456826)
- ClinicalTrials.gov: ABF-101 dose-escalation study (NCT07330674)
- ClinicalTrials.gov: Opti-GAIN CTx001 study (NCT07392255)
- ClinicalTrials.gov: BS01 in geographic atrophy (NCT07158775)
- ClinicalTrials.gov: SGLT2 inhibitors in geographic atrophy (NCT07174687)
- ClinicalTrials.gov: Pozelimab for geographic atrophy (NCT07230834)
- ClinicalTrials.gov: ONL1204 in geographic atrophy (NCT06659445)
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.